Clinical analysis of pembrolizumab therapy for recurrent or metastatic head and neck cancer: A single center retrospective study
Author:
Affiliation:
1. Department of Otolaryngology-Head ＆ Neck Surgery, Saga University Faculty of Medicine
2. Department of Otolaryngology, Takagi Hospital
Publisher
Japan Society for Head and Neck Cancer
Link
https://www.jstage.jst.go.jp/article/jjhnc/50/1/50_13/_pdf
Reference11 articles.
1. 1） Burtness B., Harrington K.J., Greil R., et al: Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck （KEYNOTE-048）: a randomised, open-label, phase 3 study. The Lancet 394：1915-1928, 2019 doi: https://doi.org/10.1016/S0140-6736(19)32591-7
2. 2） Burtness B., Rischin D., Greil R., et al: Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 40：2321-2332, 2022 doi: 10.1200/jco.21.02198
3. 3） Matsuo M., Yasumatsu R., Masuda M., et al: Five-year Follow-up of Patients With Head and Neck Cancer Treated With Nivolumab and Long-term Responders for Over Two Years. In Vivo 36：1881-1886, 2022 doi: 10.21873/invivo.12907
4. 4） Berner F., Bomze D., Diem S., et al: Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. JAMA Oncol 5：1043-1047, 2019 doi: 10.1001/jamaoncol.2019.0402
5. 5） Rogado J., Sánchez-Torres J.M., Romero-Laorden N., et al: Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. European journal of cancer （Oxford, England: 1990） 109：21-27, 2019 doi: 10.1016/j.ejca.2018.10.014
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3